Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Academic Medicine : Journal of the Association of American Medical Colleges|May 29, 2000
The two fundamental duties of the physicianB Minogue
European Journal of Pharmacology|December 1, 1987
Fasting and L-364,718 prevent cholecystokinin-induced elevations of plasma insulin levelsJ E Reagan, J L Robinson, V J Lotti, et al.
Endocrinology|September 1, 1988
Evaluation of novel parathyroid hormone analogs using a bovine renal membrane receptor binding assayM E Goldman, M Chorev, J E Reagan, et al.
Clinical Therapeutics|November 1, 1995
Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitisT J Simon, W G Roberts, R G Berlin, et al.
International Journal of Peptide and Protein Research|November 1, 1990
Effects of hydrophobic substitutions at position 18 on the potency of parathyroid hormone antagonistsM Chorev, E Roubini, M E Goldman, et al.
Peptides|January 1, 1991
Biological activity of parathyroid hormone antagonists substituted at position 13M Chorev, E Roubini, R L McKee, et al.
BMC Genomics|March 7, 2019
Systems based analysis of human embryos and gene networks involved in cell lineage allocationH L Smith, A Stevens, B Minogue, et al.
The Journal of Clinical Endocrinology and Metabolism|September 16, 1999
Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trialR Lindsay, F Cosman, R A Lobo, et al.
Endocrinology|November 1, 1988
A new highly potent parathyroid hormone antagonist: [D-Trp12,Tyr34]bPTH-(7-34)NH2M E Goldman, R L McKee, M P Caulfield, et al.
Biochemistry|February 13, 1990
Modifications of position 12 in parathyroid hormone and parathyroid hormone related protein: toward the design of highly potent antagonistsM Chorev, M E Goldman, R L McKee, et al.
Pageof 2